Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both PD-L1 positive metastatic and early-stage triple-negative breast cancer, while ongoing clinical trials seek to expand the current treatment landscape for immune checkpoint inhibitors in hormone receptor positive and HER2 positive breast cancer. Antibody drug conjugates are FDA approved for triple negative and HER2+ disease, and are being studied in combination with immune checkpoint inhibitors. Vaccines and bispecific antibodies are areas of active research. Studies of cellular therapies such as tumor infiltrating lymphocytes, chimeric antigen receptor-T cells and T cell receptor engineered cells are promising and ongoing. This review provides an update of recent major clinical trials of immunotherapy in breast cancer and discusses future directions in the treatment of breast cancer.

中文翻译：

---

当前和未来的乳腺癌免疫疗法


乳腺癌免疫治疗领域已经取得了重大治疗进展。免疫检查点抑制剂 pembrolizumab 联合化疗已获得 FDA 批准用于治疗 PD-L1 阳性转移性和早期三阴性乳腺癌，而正在进行的临床试验旨在扩大免疫检查点抑制剂在激素受体阳性和 HER2 阳性乳腺癌中的当前治疗前景。抗体药物偶联物已获得 FDA 批准用于三阴性和 HER2+ 疾病，并且正在与免疫检查点抑制剂联合使用进行研究。疫苗和双特异性抗体是积极研究的领域。肿瘤浸润淋巴细胞、嵌合抗原受体-T 细胞和 T 细胞受体工程细胞等细胞疗法的研究前景广阔且正在进行中。本综述提供了最近乳腺癌免疫治疗主要临床试验的最新进展，并讨论了乳腺癌治疗的未来方向。